Table 2.
The association of serum AnxA2 levels with clinicopathological characteristics in breast cancer patients.
| Pathological Factors | Cases (n) | Serum AnxA2 Levels (Mean ± SEM, ng/mL) |
Unpaired t-Test |
p-Value |
|---|---|---|---|---|
| Tumor Size (cm): | ||||
| ≤2 | 84 | 10.94 ± 0.696 | 0.061 | p = 0.9512 |
| >2 | 65 | 11.00 ± 0.718 | ||
| Menopausal Status: | ||||
| Premenopausal | 28 | 10.01 ± 1.071 | ||
| Perimenopausal | 8 | 10.11 ± 2.504 | 0.039 | p = 0.9687 |
| Postmenopausal | 115 | 11.53 ± 0.616 | 1.119 | p = 0.2651 |
| Lymph Node Metastasis: | ||||
| Positive | 58 | 9.946 ± 0.667 | 1.552 | p = 0.1229 |
| Negative | 89 | 11.54 ± 0.708 | ||
| ER: | ||||
| Negative | 110 | 13.74 ± 0.563 | 9.426 | p < 0.0001 |
| Positive | 50 | 5.410 ± 0.425 | ||
| HER2: | ||||
| Negative | 106 | 11.74 ± 0.724 | 1.683 | p = 0.0943 |
| Positive | 54 | 9.938 ± 0.485 | ||
| ER/HER2 vs. TNBC: | ||||
| Triple-negative | 56 | 17.40 ± 0.718 | 12.84 | p < 0.0001 |
| ER + HER2 positive | 104 | 7.761 ± 0.392 | ||